CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical oncologists, hematologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of lung cancer.
  
  LEARNING OBJECTIVES

  • Evaluate available data documenting the efficacy and safety of anti-PD-1/PD-L1 antibody-based approaches as neoadjuvant or adjuvant therapy for nonmetastatic non-small cell lung cancer (NSCLC).
  • Appraise the FDA approval of anti-PD-L1 antibody consolidation therapy for unresectable Stage III NSCLC, and appropriately integrate this strategy into clinical practice.
  • Acknowledge the FDA approval of adjuvant EGFR tyrosine kinase inhibitor (TKI) therapy for localized NSCLC with EGFR mutations, and identify patients for whom this novel approach would be warranted.
  • Review published research data documenting the safety and efficacy of EGFR TKIs alone or with other systemic therapies for metastatic NSCLC with an EGFR tumor mutation, and appropriately apply this information in patient care.
  • Assess the efficacy and safety of commercially available ALK inhibitors for metastatic NSCLC with an ALK rearrangement, and apply this understanding to the selection and sequencing of these drugs.
  • Recall other oncogenic pathways mediating the pathogenesis of tumors in unique patient subsets (ie, ROS1, RET, MET, HER2, KRAS), and recall published data with commercially available and experimental agents exploiting these targets.
  • Review recent therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination for metastatic NSCLC, and discern how these approaches can be optimally employed in the management of this disease.
  • Appreciate available clinical trial findings informing the use of immune checkpoint inhibitors in combination with platinum-based chemotherapy for previously untreated extensive-stage small cell lung cancer (SCLC).
  • Design an optimal approach to the clinical care of patients with progressive SCLC, considering prior therapeutic exposure, symptomatology and other factors.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  HOW TO USE THIS CME ACTIVITY
  This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Justin F Gainor, MD
  Director, Center for Thoracic Cancers at Massachusetts General Hospital
  Director of Targeted Immunotherapy in the Henri and Belinda Termeer Center for Targeted Therapies
  Associate Professor of Medicine, Harvard Medical School
  Massachusetts General Hospital
  Boston, Massachusetts
  
  Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Gilead Sciences Inc, Helsinn Healthcare SA, Incyte Corporation, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Novartis, Oncorus, Pfizer Inc, Regeneron Pharmaceuticals Inc, Takeda Pharmaceuticals USA Inc; Contracted Research: Adaptimmune, ALX Oncology, Array BioPharma Inc, a subsidiary of Pfizer Inc, Blueprint Medicines, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Jounce Therapeutics, Merck, Moderna, Novartis, Scholar Rock, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company; Employment (Immediate Family Member): Ironwood Pharmaceuticals.
  
  Corey J Langer, MD
  Director of Thoracic Oncology
  Abramson Cancer Center
  Professor of Medicine
  Perelman School of Medicine
  University of Pennsylvania
  Philadelphia, Pennsylvania
  
  Advisory Committee: AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, GlaxoSmithKline, Guardant Health, Lilly, Merck, Pfizer Inc, Takeda Pharmaceuticals USA Inc; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Gilead Sciences Inc, Lilly, Merck, Novartis, Novocure Inc, Regeneron Pharmaceuticals Inc; Contracted Research: Advantagene Inc, Amgen Inc, Lilly, Merck, Takeda Pharmaceuticals USA Inc, Trizell; Data and Safety Monitoring Board/Committee: US Department of Veterans Affairs, OncocyteRx.
  
  Luis Paz-Ares, MD, PhD
  Chair of the Medical Oncology Department at the Hospital Universitario 12 de Octubre
  Associate Professor at the Universidad Complutense
  Head of the Lung Cancer Unit at the National Oncology Research Center
  Madrid, Spain
  
  Board: GENOMICA SAU; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp, Pfizer Inc; Speakers Bureau: Amgen Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Bristol-Myers Squibb Company, Daiichi Sankyo Inc, GlaxoSmithKline, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pfizer Inc, PharmaMar, Roche Laboratories Inc, Sanofi Genzyme, Servier Pharmaceuticals LLC, Takeda Pharmaceuticals USA Inc.
  
  Heather Wakelee, MD
  Professor of Medicine
  Chief, Division of Oncology
  Interim Medical Director, Stanford Cancer Center
  Deputy Director, Stanford Cancer Institute
  President, International Association for the Study of Lung Cancer (IASLC)
  Stanford, California
  
  Advisory Board: AstraZeneca Pharmaceuticals LP, Blueprint Medicines, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Janssen, Biotech Inc, Merck, Mirati Therapeutics; Research Funding: ACEA Biosciences Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Clovis Oncology, Genentech, a member of the Roche Group, Helsinn Healthcare SA, Merck, Novartis, Seagen Inc, Xcovery.
  
  Jared Weiss, MD
  Professor of Medicine
  UNC School of Medicine
  Lineberger Comprehensive Cancer Center
  Chapel Hill, North Carolina
  
  Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Azitra, Boehringer Ingelheim Pharmaceuticals Inc, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Jazz Pharmaceuticals Inc, Lilly, Nanobiotix, Pfizer Inc, Regeneron Pharmaceuticals Inc, Saatchi & Saatchi Wellness, Sumitomo Dainippon Pharma Oncology Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics Inc, Inspirna, Merck; Data and Safety Monitoring Board/Committee: BeiGene Ltd, EMD Serono Inc, Jounce Therapeutics; Ownership Interest: Achilles Therapeutics, Lyell, Nuvalent, Vesselon (warrants).
  
  Helena Yu, MD
  Medical Oncologist
  Associate Attending
  Memorial Sloan Kettering Cancer Center
  New York, New York
  
  Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Blueprint Medicines, C4 Therapeutics, Cullinan Oncology, Daiichi Sankyo Inc, Janssen Biotech Inc; Research Funding (to Institution): AstraZeneca Pharmaceuticals LP, Cullinan Oncology, Daiichi Sankyo Inc, Erasca, Janssen Biotech Inc, Pfizer Inc, Novartis.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Epizyme Inc, Exact Sciences Corporation, the parent company of GHI, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Blueprint Medicines and Genentech, a member of the Roche Group, Daiichi Sankyo Inc, G1 Therapeutics Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Lilly, Regeneron Pharmaceuticals Inc and Sanofi, and Takeda Pharmaceuticals USA Inc.
  
  Release date: June 2022
  Expiration date: June 2023